ID   PAK2_HUMAN              Reviewed;         524 AA.
AC   Q13177; Q13154; Q6ISC3;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Serine/threonine-protein kinase PAK 2;
DE            EC=2.7.11.1;
DE   AltName: Full=Gamma-PAK;
DE   AltName: Full=PAK65;
DE   AltName: Full=S6/H4 kinase;
DE   AltName: Full=p21-activated kinase 2;
DE            Short=PAK-2;
DE   AltName: Full=p58;
DE   Contains:
DE     RecName: Full=PAK-2p27;
DE              Short=p27;
DE   Contains:
DE     RecName: Full=PAK-2p34;
DE              Short=p34;
DE     AltName: Full=C-t-PAK2;
GN   Name=PAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Sells M., Knause U.J., Bagrodia S., Ambrose D., Bokoch G.M.,
RA   Chernoff J.;
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 32-524, AND PROTEIN SEQUENCE OF 401-417.
RC   TISSUE=Placenta;
RX   PubMed=7744004;
RA   Martin G.A., Bollag G., McCormick F., Abo A.;
RT   "A novel serine kinase activated by rac1/CDC42Hs-dependent
RT   autophosphorylation is related to PAK65 and STE20.";
RL   EMBO J. 14:1970-1978(1995).
RN   [4]
RP   ERRATUM.
RX   PubMed=7556080;
RA   Martin G.A., Bollag G., McCormick F., Abo A.;
RL   EMBO J. 14:4385-4385(1995).
RN   [5]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=7673144; DOI=10.1074/jbc.270.36.21121;
RA   Benner G.E., Dennis P.B., Masaracchia R.A.;
RT   "Activation of an S6/H4 kinase (PAK 65) from human placenta by
RT   intramolecular and intermolecular autophosphorylation.";
RL   J. Biol. Chem. 270:21121-21128(1995).
RN   [6]
RP   CASPASE-3 CLEAVAGE AT ASP-512, FUNCTION, AND MUTAGENESIS OF ASP-212.
RX   PubMed=9171063; DOI=10.1126/science.276.5318.1571;
RA   Rudel T., Bokoch G.M.;
RT   "Membrane and morphological changes in apoptotic cells regulated by
RT   caspase-mediated activation of PAK2.";
RL   Science 276:1571-1574(1997).
RN   [7]
RP   CASPASE-3 CLEAVAGE AT ASP-512, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   LYS-278 AND THR-402.
RX   PubMed=9786869; DOI=10.1074/jbc.273.44.28733;
RA   Walter B.N., Huang Z., Jakobi R., Tuazon P.T., Alnemri E.S.,
RA   Litwack G., Traugh J.A.;
RT   "Cleavage and activation of p21-activated protein kinase gamma-PAK by
RT   CPP32 (caspase 3). Effects of autophosphorylation on activity.";
RL   J. Biol. Chem. 273:28733-28739(1998).
RN   [8]
RP   INTERACTION WITH HIV-1 NEF.
RX   PubMed=11070003; DOI=10.1128/JVI.74.23.11081-11087.2000;
RA   Arora V.K., Molina R.P., Foster J.L., Blakemore J.L., Chernoff J.,
RA   Fredericksen B.L., Garcia J.V.;
RT   "Lentivirus Nef specifically activates Pak2.";
RL   J. Virol. 74:11081-11087(2000).
RN   [9]
RP   FUNCTION (PAK-2P34), UBIQUITINATION, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 239-ILE--GLY-243 AND 246-LYS--LYS-248.
RX   PubMed=12853446; DOI=10.1074/jbc.M306494200;
RA   Jakobi R., McCarthy C.C., Koeppel M.A., Stringer D.K.;
RT   "Caspase-activated PAK-2 is regulated by subcellular targeting and
RT   proteasomal degradation.";
RL   J. Biol. Chem. 278:38675-38685(2003).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF MKNK1.
RX   PubMed=15234964; DOI=10.1074/jbc.M407337200;
RA   Orton K.C., Ling J., Waskiewicz A.J., Cooper J.A., Merrick W.C.,
RA   Korneeva N.L., Rhoads R.E., Sonenberg N., Traugh J.A.;
RT   "Phosphorylation of Mnk1 by caspase-activated Pak2/gamma-PAK inhibits
RT   phosphorylation and interaction of eIF4G with Mnk.";
RL   J. Biol. Chem. 279:38649-38657(2004).
RN   [11]
RP   INTERACTION WITH ARHGAP10, AND SUBCELLULAR LOCATION.
RX   PubMed=15471851; DOI=10.1074/jbc.M410530200;
RA   Koeppel M.A., McCarthy C.C., Moertl E., Jakobi R.;
RT   "Identification and characterization of PS-GAP as a novel regulator of
RT   caspase-activated PAK-2.";
RL   J. Biol. Chem. 279:53653-53664(2004).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   INTERACTION WITH SH3MD4.
RX   PubMed=16374509; DOI=10.1038/sj.embor.7400596;
RA   Kaerkkaeinen S., Hiipakka M., Wang J.-H., Kleino I.,
RA   Vaehae-Jaakkola M., Renkema G.H., Liss M., Wagner R., Saksela K.;
RT   "Identification of preferred protein interactions by phage-display of
RT   the human Src homology-3 proteome.";
RL   EMBO Rep. 7:186-191(2006).
RN   [14]
RP   FUNCTION (PAK-2P34), MYRISTOYLATION AT GLY-213 (PAK-2P34), AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16617111; DOI=10.1073/pnas.0600824103;
RA   Vilas G.L., Corvi M.M., Plummer G.J., Seime A.M., Lambkin G.R.,
RA   Berthiaume L.G.;
RT   "Posttranslational myristoylation of caspase-activated p21-activated
RT   protein kinase 2 (PAK2) potentiates late apoptotic events.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6542-6547(2006).
RN   [15]
RP   INTERACTION WITH SCRIB.
RX   PubMed=18716323; DOI=10.1093/hmg/ddn248;
RA   Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S.,
RA   Navarro C., Rachel R., Montcouquiol M., Sans N.,
RA   Etienne-Manneville S., Borg J.-P., Santoni M.-J.;
RT   "Scrib regulates PAK activity during the cell migration process.";
RL   Hum. Mol. Genet. 17:3552-3565(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-58; SER-141 AND THR-169,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   INTERACTION WITH ARHGEF7 AND GIT1.
RX   PubMed=19273597; DOI=10.1128/MCB.01713-08;
RA   Mitsushima M., Toyoshima F., Nishida E.;
RT   "Dual role of Cdc42 in spindle orientation control of adherent
RT   cells.";
RL   Mol. Cell. Biol. 29:2816-2827(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-141 AND SER-197, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-128, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [21]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19923322; DOI=10.1091/mbc.E09-03-0232;
RA   Hsu R.M., Tsai M.H., Hsieh Y.J., Lyu P.C., Yu J.S.;
RT   "Identification of MYO18A as a novel interacting partner of the
RT   PAK2/betaPIX/GIT1 complex and its potential function in modulating
RT   epithelial cell migration.";
RL   Mol. Biol. Cell 21:287-301(2010).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-2 AND SER-141, CLEAVAGE OF INITIATOR METHIONINE
RP   [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=21098037; DOI=10.1074/jbc.M110.156505;
RA   Wang J., Wu J.W., Wang Z.X.;
RT   "Mechanistic studies of the autoactivation of PAK2: a two-step model
RT   of cis initiation followed by trans amplification.";
RL   J. Biol. Chem. 286:2689-2695(2011).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF MAPK4 AND MAPK6.
RX   PubMed=21317288; DOI=10.1074/jbc.M110.181743;
RA   De la Mota-Peynado A., Chernoff J., Beeser A.;
RT   "Identification of the atypical MAPK Erk3 as a novel substrate for
RT   p21-activated kinase (Pak) activity.";
RL   J. Biol. Chem. 286:13603-13611(2011).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF JUN.
RX   PubMed=21177766; DOI=10.1093/carcin/bgq271;
RA   Li T., Zhang J., Zhu F., Wen W., Zykova T., Li X., Liu K., Peng C.,
RA   Ma W., Shi G., Dong Z., Bode A.M., Dong Z.;
RT   "P21-activated protein kinase (PAK2)-mediated c-Jun phosphorylation at
RT   5 threonine sites promotes cell transformation.";
RL   Carcinogenesis 32:659-666(2011).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H4.
RX   PubMed=21724829; DOI=10.1101/gad.2055511;
RA   Kang B., Pu M., Hu G., Wen W., Dong Z., Zhao K., Stillman B.,
RA   Zhang Z.;
RT   "Phosphorylation of H4 Ser 47 promotes HIRA-mediated nucleosome
RT   assembly.";
RL   Genes Dev. 25:1359-1364(2011).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-2; SER-141 AND THR-169, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-20; SER-55;
RP   SER-58; THR-60; SER-64; THR-134; SER-141; THR-143; THR-154; THR-169
RP   AND SER-197, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-139 AND SER-141, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.86 ANGSTROMS) OF 121-136.
RX   PubMed=21170023; DOI=10.1038/nature09593;
RA   Selyunin A.S., Sutton S.E., Weigele B.A., Reddick L.E., Orchard R.C.,
RA   Bresson S.M., Tomchick D.R., Alto N.M.;
RT   "The assembly of a GTPase-kinase signalling complex by a bacterial
RT   catalytic scaffold.";
RL   Nature 469:107-111(2011).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell motility, cell cycle progression, apoptosis or
CC       proliferation. Acts as downstream effector of the small GTPases
CC       CDC42 and RAC1. Activation by the binding of active CDC42 and RAC1
CC       results in a conformational change and a subsequent
CC       autophosphorylation on several serine and/or threonine residues.
CC       Full-length PAK2 stimulates cell survival and cell growth.
CC       Phosphorylates MAPK4 and MAPK6 and activates the downstream target
CC       MAPKAPK5, a regulator of F-actin polymerization and cell
CC       migration. Phosphorylates JUN and plays an important role in EGF-
CC       induced cell proliferation. Phosphorylates many other substrates
CC       including histone H4 to promote assembly of H3.3 and H4 into
CC       nucleosomes, BAD, ribosomal protein S6, or MBP. Additionally,
CC       associates with ARHGEF7 and GIT1 to perform kinase-independent
CC       functions such as spindle orientation control during mitosis. On
CC       the other hand, apoptotic stimuli such as DNA damage lead to
CC       caspase-mediated cleavage of PAK2, generating PAK-2p34, an active
CC       p34 fragment that translocates to the nucleus and promotes
CC       cellular apoptosis involving the JNK signaling pathway. Caspase-
CC       activated PAK2 phosphorylates MKNK1 and reduces cellular
CC       translation. {ECO:0000269|PubMed:12853446,
CC       ECO:0000269|PubMed:15234964, ECO:0000269|PubMed:16617111,
CC       ECO:0000269|PubMed:19923322, ECO:0000269|PubMed:21177766,
CC       ECO:0000269|PubMed:21317288, ECO:0000269|PubMed:21724829,
CC       ECO:0000269|PubMed:9171063}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by binding small G proteins. Binding
CC       of GTP-bound CDC42 or RAC1 to the autoregulatory region releases
CC       monomers from the autoinhibited dimer, enables phosphorylation of
CC       Thr-402 and allows the kinase domain to adopt an active structure
CC       (By similarity). Following caspase cleavage, autophosphorylated
CC       PAK-2p34 is constitutively active. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound
CC       CDC42/p21 and RAC1. Interacts with SH3MD4. Interacts with and
CC       activated by HIV-1 Nef. Interacts with SCRIB. Interacts with
CC       ARHGEF7 and GIT1. PAK-2p34 interacts with ARHGAP10.
CC       {ECO:0000269|PubMed:11070003, ECO:0000269|PubMed:15471851,
CC       ECO:0000269|PubMed:16374509, ECO:0000269|PubMed:18716323,
CC       ECO:0000269|PubMed:19273597}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1045887, EBI-1045887;
CC       Q15052:ARHGEF6; NbExp=4; IntAct=EBI-1045887, EBI-1642523;
CC       Q14155:ARHGEF7; NbExp=4; IntAct=EBI-1045887, EBI-717515;
CC       O55043:Arhgef7 (xeno); NbExp=8; IntAct=EBI-1045887, EBI-3649585;
CC       P55210:CASP7; NbExp=6; IntAct=EBI-1045887, EBI-523958;
CC       P60953:CDC42; NbExp=4; IntAct=EBI-1045887, EBI-81752;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-1045887, EBI-401755;
CC       P08631:HCK; NbExp=2; IntAct=EBI-1045887, EBI-346340;
CC       P42858:HTT; NbExp=2; IntAct=EBI-1045887, EBI-466029;
CC       P53667:LIMK1; NbExp=2; IntAct=EBI-1045887, EBI-444403;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1045887, EBI-389883;
CC       P63000:RAC1; NbExp=4; IntAct=EBI-1045887, EBI-413628;
CC       P04049:RAF1; NbExp=2; IntAct=EBI-1045887, EBI-365996;
CC       Q9H4E5:RHOJ; NbExp=5; IntAct=EBI-1045887, EBI-6285694;
CC       Q8TEJ3:SH3RF3; NbExp=2; IntAct=EBI-1045887, EBI-7975674;
CC       Q9BX66:SORBS1; NbExp=2; IntAct=EBI-1045887, EBI-433642;
CC       O94875:SORBS2; NbExp=2; IntAct=EBI-1045887, EBI-311323;
CC       O60504:SORBS3; NbExp=6; IntAct=EBI-1045887, EBI-741237;
CC       P12931:SRC; NbExp=2; IntAct=EBI-1045887, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Serine/threonine-protein kinase PAK 2:
CC       Cytoplasm. Note=MYO18A mediates the cellular distribution of the
CC       PAK2-ARHGEF7-GIT1 complex to the inner surface of the cell
CC       membrane.
CC   -!- SUBCELLULAR LOCATION: PAK-2p34: Nucleus. Cytoplasm, perinuclear
CC       region. Membrane; Lipid-anchor. Note=Interaction with ARHGAP10
CC       probably changes PAK-2p34 location to cytoplasmic perinuclear
CC       region. Myristoylation changes PAK-2p34 location to the membrane.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Higher levels seen in
CC       skeletal muscle, ovary, thymus and spleen.
CC   -!- PTM: Full length PAK2 is autophosphorylated when activated by
CC       CDC42/p21. Following cleavage, both peptides, PAK-2p27 and PAK-
CC       2p34, become highly autophosphorylated, with PAK-2p27 being
CC       phosphorylated on serine and PAK-2p34 on threonine residues,
CC       respectively. Autophosphorylation of PAK-2p27 can occur in the
CC       absence of any effectors and is dependent on phosphorylation of
CC       Thr-402, because PAK-2p27 is acting as an exogenous substrate.
CC   -!- PTM: During apoptosis proteolytically cleaved by caspase-3 or
CC       caspase-3-like proteases to yield active PAK-2p34.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation.
CC       {ECO:0000269|PubMed:12853446}.
CC   -!- PTM: PAK-2p34 is myristoylated. {ECO:0000269|PubMed:16617111}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAK2ID41634ch3q29.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U24153; AAA65442.1; -; mRNA.
DR   EMBL; BC069613; AAH69613.1; -; mRNA.
DR   EMBL; U25975; AAA75468.1; -; mRNA.
DR   CCDS; CCDS3321.1; -.
DR   PIR; S58682; S58682.
DR   RefSeq; NP_002568.2; NM_002577.4.
DR   RefSeq; XP_011511172.1; XM_011512870.2.
DR   RefSeq; XP_016861990.1; XM_017006501.1.
DR   UniGene; Hs.518530; -.
DR   PDB; 3PCS; X-ray; 2.86 A; E/F/G/H=121-136.
DR   PDBsum; 3PCS; -.
DR   ProteinModelPortal; Q13177; -.
DR   SMR; Q13177; -.
DR   BioGrid; 111098; 84.
DR   DIP; DIP-38249N; -.
DR   IntAct; Q13177; 47.
DR   MINT; MINT-235655; -.
DR   STRING; 9606.ENSP00000314067; -.
DR   BindingDB; Q13177; -.
DR   ChEMBL; CHEMBL4487; -.
DR   GuidetoPHARMACOLOGY; 2134; -.
DR   iPTMnet; Q13177; -.
DR   PhosphoSitePlus; Q13177; -.
DR   SwissPalm; Q13177; -.
DR   BioMuta; PAK2; -.
DR   DMDM; 143811432; -.
DR   OGP; Q13177; -.
DR   EPD; Q13177; -.
DR   MaxQB; Q13177; -.
DR   PaxDb; Q13177; -.
DR   PeptideAtlas; Q13177; -.
DR   PRIDE; Q13177; -.
DR   DNASU; 5062; -.
DR   Ensembl; ENST00000327134; ENSP00000314067; ENSG00000180370.
DR   GeneID; 5062; -.
DR   KEGG; hsa:5062; -.
DR   UCSC; uc003fwy.4; human.
DR   CTD; 5062; -.
DR   DisGeNET; 5062; -.
DR   GeneCards; PAK2; -.
DR   H-InvDB; HIX0030815; -.
DR   HGNC; HGNC:8591; PAK2.
DR   HPA; CAB007794; -.
DR   MIM; 605022; gene.
DR   neXtProt; NX_Q13177; -.
DR   OpenTargets; ENSG00000180370; -.
DR   PharmGKB; PA32918; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   eggNOG; ENOG410XP4K; LUCA.
DR   GeneTree; ENSGT00860000133680; -.
DR   HOGENOM; HOG000234202; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q13177; -.
DR   KO; K04410; -.
DR   OMA; MTSASHK; -.
DR   OrthoDB; EOG091G04H8; -.
DR   PhylomeDB; Q13177; -.
DR   TreeFam; TF105351; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-211728; Regulation of PAK-2p34 activity by PS-GAP/RHG10.
DR   Reactome; R-HSA-211733; Regulation of activated PAK-2p34 by proteasome mediated degradation.
DR   Reactome; R-HSA-211736; Stimulation of the cell death response by PAK-2p34.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-428540; Activation of Rac.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   SignaLink; Q13177; -.
DR   SIGNOR; Q13177; -.
DR   ChiTaRS; PAK2; human.
DR   EvolutionaryTrace; Q13177; -.
DR   GeneWiki; PAK2; -.
DR   GenomeRNAi; 5062; -.
DR   PMAP-CutDB; Q13177; -.
DR   PRO; PR:Q13177; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000180370; -.
DR   CleanEx; HS_PAK2; -.
DR   ExpressionAtlas; Q13177; baseline and differential.
DR   Genevisible; Q13177; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0048365; F:Rac GTPase binding; IPI:CAFA.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0031267; F:small GTPase binding; IPI:CAFA.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0060996; P:dendritic spine development; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2001271; P:negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis; IDA:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; TAS:ProtInc.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Apoptosis; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Growth regulation; Host-virus interaction; Kinase; Lipoprotein;
KW   Membrane; Myristate; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    524       Serine/threonine-protein kinase PAK 2.
FT                                /FTId=PRO_0000086465.
FT   CHAIN         2    212       PAK-2p27.
FT                                /FTId=PRO_0000304922.
FT   CHAIN       213    524       PAK-2p34.
FT                                /FTId=PRO_0000304923.
FT   DOMAIN       74     87       CRIB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00057}.
FT   DOMAIN      249    499       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     255    263       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       69    137       Autoregulatory region. {ECO:0000250}.
FT   REGION       69    112       GTPase-binding. {ECO:0000250}.
FT   MOTIF       245    251       Nuclear localization signal.
FT   ACT_SITE    367    367       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     278    278       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        212    213       Cleavage; by caspase-3 or caspase-3-like
FT                                proteases.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      55     55       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      58     58       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      60     60       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      62     62       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8CIN4}.
FT   MOD_RES      64     64       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     128    128       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     134    134       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     139    139       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     141    141       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     143    143       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     152    152       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8CIN4}.
FT   MOD_RES     154    154       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     169    169       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     197    197       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     402    402       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305}.
FT   LIPID       213    213       N-myristoyl glycine; in form PAK-2p34.
FT                                {ECO:0000269|PubMed:16617111}.
FT   MUTAGEN     212    212       D->N: Inhibits caspase-mediated cleavage.
FT                                {ECO:0000269|PubMed:9171063}.
FT   MUTAGEN     213    213       G->A: Abolishes myristoylation of PAK-
FT                                2p34 and membrane location.
FT   MUTAGEN     239    243       IVSIG->REGRS: Abolishes nuclear export.
FT                                {ECO:0000269|PubMed:12853446}.
FT   MUTAGEN     246    248       KKK->MHE: Greatly inhibits nuclear
FT                                localization.
FT                                {ECO:0000269|PubMed:12853446}.
FT   MUTAGEN     278    278       K->R: Abolishes kinase activity and
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:9786869}.
FT   MUTAGEN     402    402       T->A: Abolishes kinase activity and
FT                                greatly inhibits autophosphorylation of
FT                                PAK-2p27 and PAK-2p34.
FT                                {ECO:0000269|PubMed:9786869}.
FT   CONFLICT     90     90       A -> T (in Ref. 3; AAA75468).
FT                                {ECO:0000305}.
FT   CONFLICT    150    150       F -> L (in Ref. 1; AAA65442).
FT                                {ECO:0000305}.
FT   CONFLICT    225    225       T -> P (in Ref. 1; AAA65442).
FT                                {ECO:0000305}.
FT   CONFLICT    258    258       G -> R (in Ref. 2; AAH69613).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       G -> R (in Ref. 3; AAA75468).
FT                                {ECO:0000305}.
FT   CONFLICT    338    338       T -> TA (in Ref. 1; AAA65442).
FT                                {ECO:0000305}.
FT   HELIX       123    126       {ECO:0000244|PDB:3PCS}.
SQ   SEQUENCE   524 AA;  58043 MW;  00A7CD15F93D4180 CRC64;
     MSDNGELEDK PPAPPVRMSS TIFSTGGKDP LSANHSLKPL PSVPEEKKPR HKIISIFSGT
     EKGSKKKEKE RPEISPPSDF EHTIHVGFDA VTGEFTGMPE QWARLLQTSN ITKLEQKKNP
     QAVLDVLKFY DSNTVKQKYL SFTPPEKDGF PSGTPALNAK GTEAPAVVTE EEDDDEETAP
     PVIAPRPDHT KSIYTRSVID PVPAPVGDSH VDGAAKSLDK QKKKTKMTDE EIMEKLRTIV
     SIGDPKKKYT RYEKIGQGAS GTVFTATDVA LGQEVAIKQI NLQKQPKKEL IINEILVMKE
     LKNPNIVNFL DSYLVGDELF VVMEYLAGGS LTDVVTETCM DEAQIAAVCR ECLQALEFLH
     ANQVIHRDIK SDNVLLGMEG SVKLTDFGFC AQITPEQSKR STMVGTPYWM APEVVTRKAY
     GPKVDIWSLG IMAIEMVEGE PPYLNENPLR ALYLIATNGT PELQNPEKLS PIFRDFLNRC
     LEMDVEKRGS AKELLQHPFL KLAKPLSSLT PLIMAAKEAM KSNR
//
